EY has acquired Aqurance for an undisclosed amount. The transaction, effective October 9th, 2025, sees Aqurance integrate into EY, operating as EY Aqurance. Aqurance is a specialized digital transformation partner for the pharmaceutical industry, known for its expertise in enhancing CRM Effectiveness, empowering Digital Marketing Solutions, and leveraging the power of data.
Founded by SaaS and life sciences specialists, Aqurance guides clients through digital transformation initiatives by optimizing commercial and development operations. Its comprehensive solutions include expertise in Veeva Vault applications for Research & Development and Quality, alongside commercial services, medical content, business analytics, data services, and market research. The company has a proven track record in delivering impactful results and fostering a culture of growth.
This acquisition is a strategic move for EY, a global professional services organization. It aims to significantly broaden and strengthen EY's support for life sciences companies navigating the complex digital age. Aqurance's deep understanding of the pharmaceutical landscape and its focus on data-driven transformation align with EY's commitment to delivering advanced client solutions. The integration is expected to create synergies that enhance service offerings in areas such as digital strategy, data integration, and regulatory compliance within the life sciences sector.
The combined entity will provide an expanded suite of end-to-end digital transformation capabilities, particularly leveraging Aqurance's specialized proficiency in Veeva platforms and data-powered strategies. This aims to enable life sciences organizations to accelerate their digital journeys, optimize operations, and achieve their research and commercial objectives more effectively in a rapidly evolving market.